600351.SH
亚宝药业
SSE · Healthcare · Medical - Pharmaceuticals · CN
CNY 6.78
−1.31%Price chart
Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
7.4x
Market Cap
CNY 4.69B
MomentumView details →
1D Return
−1.31%
YTD Return
+2.62%
RSI (14)
43.4
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
7.4x
Market Cap
CNY 4.69B
RSI (14)
43.4
MomentumView details →
1D Return
−1.31%
YTD Return
+2.62%
Similar companies
Latest newsMore news →
Yabao Pharmaceutical adjusted the upper limit of its share buyback price to 6.75 yuan per share, effective from September 1, 2026, due to the implementation of the 2026 interim dividend distribution.8d agoOn August 1, 2026, 47 Chinese A-share companies disclosed various stages of stock buyback progress, including shareholder proposals, initial plans, implementation updates, and completed buybacks.35d agoYabao Pharmaceutical announced a plan to repurchase its own shares for 100 million to 200 million yuan at a price not exceeding 6.95 yuan per share, with the repurchased shares to be cancelled to reduce registered capital, funded by its own funds, within 12 months after shareholder approval.36d ago